Wellgistics Health, Inc.

WGRX

$3.52

+0.00%

2026-09-04 09:30:00 EDT+$0.00

Healthcare

Medical - Distribution

NASDAQ

Inactive

Wellgistics Health, Inc. functions as a primary wholesaler and distributor of pharmaceutical products throughout the United States, catering to both drug manufacturers ...

Fundamental Analysis of WGRX

Key Strengths

Integrated model combining distribution/3PL with health-tech workflows for independent pharmacies (potential for cross-sell and higher switching costs)

Service focus on small-to-mid sized pharmaceutical producers and independent retail pharmacies, a segment that can be underserved by larger logistics players

Risk Factors

Sustained profitability losses: TTM net margin ~-11% and operating margin ~-7.2%, indicating weak operating leverage so far

Liquidity and working-capital strain: very low current ratio (~0.143) and quick ratio (~0.105) with highly negative working capital

Profitability

Net Margin-1100.30%

Operating Margin-719.27%

Valuation

P/E Ratio-0.07x

Current Ratio0.14

Efficiency

ROE877.58%

ROA-269.47%

Fundamental Analysis of WGRX

Wellgistics Health, Inc. (WGRX) is a newly scaled healthcare services and health-tech enablement platform serving independent pharmacies and pharmaceutical manufacturers through wholesale/distribution, third-party logistics (3PL), and a technology-led prescription transfer and concierge workflow (DelivMeds). The company’s fundamental profile is currently dominated by early-stage scale-up and profitability pressure: TTM margins are negative across the board (gross margin approximately -1.25%, operating margin about -7.19%, net margin about -11.00%), with negative EBITDA margin (-7.07%). This indicates that current revenue generation is not yet converting into operating and free cash flow sufficient to support growth internally. From a balance-sheet/working-capital perspective, the provided TTM metrics signal constrained liquidity and heavy working-capital needs. The current ratio is extremely low (~0.143) and quick ratio is ~0.105, while working capital is deeply negative. The cash ratio is also low (~0.062). Payment-cycle metrics show a very long days-payables-outstanding relative to days-sales-outstanding, which may help fund operations temporarily but can also reflect vendor/financing dependency. Cash generation is weak: operating cash flow and free cash flow yields are negative (freeCashFlowYieldTTM about -1.57; EV/FCF is also negative), implying that investors should treat the business as requiring continued external funding and/or improved cash conversion to reach sustained value creation. On valuation, traditional earnings multiples are not meaningful because TTM earnings are negative (P/E is shown as ~-0.074). Price-to-sales is ~1.08, but in loss-making companies this metric may not provide durable downside protection without evidence of improving unit economics. Overall, current fundamentals suggest a speculative turnaround/early growth situation rather than a mature, cash-generative healthcare distributor. The investment case hinges on whether Wellgistics can (1) improve gross and operating margins through scale and better logistics economics, (2) strengthen liquidity and reduce working-capital strain, and (3) demonstrate that its platform enables defensible pharmacy/manufacturer retention and volume growth without proportionally increasing costs. Until profitability and cash-flow sustainability improve, risk remains elevated.

Key Strengths of WGRX

Integrated model combining distribution/3PL with health-tech workflows for independent pharmacies (potential for cross-sell and higher switching costs)
Service focus on small-to-mid sized pharmaceutical producers and independent retail pharmacies, a segment that can be underserved by larger logistics players
Platform-led prescription transfer/concierge concept (DelivMeds) could improve operational efficiency and customer stickiness if adoption scales
Established distribution and logistics capabilities that can benefit from volume aggregation as pharmacy networks expand
Healthcare-focused compliance and operational infrastructure needs can create barriers to entry once scale is achieved

Risk Factors of WGRX

Sustained profitability losses: TTM net margin ~-11% and operating margin ~-7.2%, indicating weak operating leverage so far
Liquidity and working-capital strain: very low current ratio (~0.143) and quick ratio (~0.105) with highly negative working capital
Negative cash flow profile: negative operating/FCF-related metrics suggest ongoing reliance on external financing and careful runway management
Valuation/earnings uncertainty: negative earnings make multiples (P/E, EV/EBITDA, EV/FCF) unreliable for forecasting intrinsic value
Working-capital funding risk tied to supplier payment terms and bank asset-based financing (interest rate and credit availability risk)
Regulatory/compliance risk typical of healthcare distribution and health-tech (HIPAA, FDA/FTC/healthcare compliance, privacy/security)
Industry and macro risks: healthcare utilization and pharmacy reimbursement pressures, plus inflationary pressures on healthcare-related pricing and demand

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$8.67M

-0.1x

P/E Ratio

1.1x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin-125.11%

Net Profit Margin-1100.30%

Debt/Equity Ratio-1.67

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of WGRX

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of WGRX

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	-1031.72%	—	—	Flat
Operating Margin	—	-412.68%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of WGRX

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	0.143	—	—	Flat
Quick Ratio	—	0.105	—	—	Flat
Debt / Equity	—	-1.673	—	—	Flat

Valuation of WGRX

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	-0.11x	—	—	Flat
P/B	—	-0.41x	—	—	Flat

Supply Chain of WGRX

RELATIONS

Upstream

Protega PharmaceuticalsTheracosBioTollo HealthGeneric Pharmaceutical Manufacturers (200+ unnamed suppliers)OptiSource Solutions LLCPiramal Pharma SolutionsNSE:PIRAMALPH

Downstream

Wells Pharmacy NetworkAxia Medical SolutionsIndependent Pharmacy Network (6,500+ pharmacies)Community Specialty Pharmacy, LLCDataVault AI Inc.NASDAQ:DVLTKare PharmTech / Kare Rx HubOptiSource Solutions LLCNFL Alumni Health

Proxies

McKesson CorporationNYSE:MCK Cencora, Inc. (formerly AmerisourceBergen)NYSE:COR Cardinal Health, Inc.NYSE:CAH GoodRx Holdings, Inc.NASDAQ:GDRX

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer